References
- Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28 896 women. N Engl J Med 1988; 319: 1681–92
- Williams C J, Buchanan R B. Management of advanced or metastatic breast cancer. The medical management of breast cancer, C J Williams, R B Buchanan. Castle House Publ Ltd., Kent 1987; 148–90
- Nolvadex Adjuvant Trial Organization. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer. Lancet 1985; 1: 836–40
- Ribeiro G, Palmer M K. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J 1984; 1: 827–30
- Breast Cancer Trials Committee, Scottish Cancer Trials Office. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Lancet 1987; 2: 171–5
- Peto R. (1986) Presentation to the consensus development Conference on Adjuvant Chemotherapy for Breast Cancer. September 9–11, 1985. Bethesda, 71, NCI Monographs No. 1
- Rose C, Mouridsen H. Treatment of advanced breast cancer with tamoxifen. Rec Results Cancer Res 1984; 91: 230–42
- Stoll B. Combination endocrine therapy-concurrent or sequential?. Endocrine management of cancer. Contemporary therapy, B Stoll. Karger, Basel 1988; Vol. 2: 80–101
- Kvinnsland S, Gundersen S. Prospects for alternating endocrine therapy. Endocrine management of cancer. Vol. 2. Contemporary therapy, B Stoll. Karger, Basel 1988; 119–25
- Gundersen S, Kvinnsland S, Lundgren S, et al. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat 1989, (Accepted.)
- Lippman M E. Steroid hormone receptors and mechanisms of growth regulation of human breast cancer. Diagnosis and management of breast cancer, M E Lippman, A S Lichter, D N Danforth. WB Saunders, Philadelphia 1988; 326–47
- Fisher B, Redmond C, Brown A, et al. Influence of tumor estrogen and progesterone receptor levels on the response to tamoxifen and chemotherapy in primary breast cancer. J Clin Oncol 1983; 1: 227–41
- Rose C, Thorpe S M, Andersen K W, et al. Beneficial effect of adjuvant tamoxifen therapy in primary breast cancer patients with high estrogen receptor levels. Lancet 1985; 1: 16–9
- Rutquist L E, Cedermark B, Glas U, et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 1987; 10: 255–66
- Lea O, Kvinnsland S, Thorsen T. Androgen receptors in human breast cancer. Cancer Res 1989; 49: 7162–7
- Fernander T, Rutquist L E, Cedermark B, et al. Adjuvant tamoxifen in early breast cancer: The incidence of new primary cancers. Lancet 1988; 2: 117–20
- Furr B, Jordan V C. The pharmacology and clinical uses of tamoxifen. Pharmac Ther 1984; 25: 127–205